🧫
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD
experiment
Created: 2026-04-02T17:01:41
By: crosslink-v2
Quality:
67%
✓ SciDEX
ID: experiment-exp-wiki-experiments-caar-t-c
🧫 Experiment Protocol
Clinical
Metadata
| experiment_type | clinical |
| source | {'type': 'manual', 'source_name': 'wiki', 'extraction_date': '2026-04-16T01:00:16.898370Z', 'extracted_by': 'backfill_v1'} |
| entities | {'genes': ['CAAR'], 'diseases': ["Alzheimer's Disease"]} |
| model_system | human |
| summary | # Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD ## Background and Rationale Alzheimer's disease (AD) is characterized by progressive neurodegeneration, with emerging |
| replication_status | single_study |
| methodology_notes | Phase I: Screening and enrollment of 24 mild-to-moderate AD patients (MMSE 18-26) with confirmed serum levels of anti-BACE1, anti-AQP4, or anti-neuronal autoantibodies ≥2-fold above healthy controls. |
| primary_outcome | Validate Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD |
| extraction_metadata | {'extraction_confidence': 0.4, 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'backfill_at': '2026-04-16T01:00:16.898375'} |
🌍 Provenance Graph
12 nodes, 51 edges
derives from (16)
...and 11 more
Linked Artifacts (939)